Pear Therapeutics, Inc. Class A Common Stock
PEAR
PEAR was delisted on the 18th of April, 2023.
49 hedge funds and large institutions have $385M invested in Pear Therapeutics, Inc. Class A Common Stock in 2022 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 2 closing their positions.
1,200% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 2
96% more funds holding
Funds holding: 25 → 49 (+24)
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
17% less capital invested
Capital invested by funds: $464M → $385M (-$78.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.92M |
| 2 |
BlackRock
New York
|
+$1.89M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.03M |
| 4 |
HF
HRT Financial
New York
|
+$685K |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
+$561K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AGM
Alpine Global Management
New York
|
-$2.59M |
| 2 |
E
Ergoteles
New York
|
-$225K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$20.6K |
| 4 |
PCM
Penserra Capital Management
Orinda,
California
|
-$6.15K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$6K |
PEAR Hedge Fund Activity: Q1 2022 in Review
49 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Pear Therapeutics, Inc. Class A Common Stock (PEAR) for Q1 2022, worth a combined $385M — down 17% from $464M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new PEAR positions and 2 closed out — a net gain of 24 holders — while 5 added to existing stakes and 4 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.92M. The largest seller was Alpine Global Management, cutting an estimated $2.59M.
- 49 institutional investors held Pear Therapeutics, Inc. Class A Common Stock (PEAR) as of Q1 2022, up from 25 in Q4 2021.
- Funds reported $385M of Pear Therapeutics, Inc. Class A Common Stock stock for Q1 2022, down 17% quarter-over-quarter.
- 26 funds opened new Pear Therapeutics, Inc. Class A Common Stock positions in Q1 2022 and 2 closed out, a net change of +24 holders.
- The largest Pear Therapeutics, Inc. Class A Common Stock buyer in Q1 2022 was Vanguard Group, an estimated $1.92M added.
- The largest Pear Therapeutics, Inc. Class A Common Stock seller in Q1 2022 was Alpine Global Management, an estimated $2.59M sold.
Based on aggregated 13F filings for Q1 2022.